TSLP and dermatitis: Of the many indole derivatives currently under investigation [94,95,96,97], the work by Yu et al. demonstrated the potential of indole-3-aldehyde treatments for lesional and non-lesional AD patients by attenuating skin inflammation and TSLP keratinocyte expression in an AD-like dermatitis murine model (MC903) [98].